L&K Biomed Signs Supply Deal with U.S. Precision Spine, Expands North American Push Amid 'Medicare Policy Tailwinds' View original image

L&K Biomed is accelerating its push into the North American market, having signed a sales agreement for cervical expandable cages with Precision Spine, a U.S. distributor of spinal medical devices. The deal follows a sales agreement with global medical device company Medtronic for lumbar products, giving the company a local sales partnership for cervical products as well.


L&K Biomed said on Nov. 5 that its U.S. subsidiary, L&K Spine, had signed an agreement with Precision Spine to expand the market for BluEX-C, its cervical expandable cage.


BluEX-C achieved an early market foothold, with the company completing product registration at 29 hospitals in the United States within two months of its launch. L&K Biomed plans to expand product supply through Precision Spine's local distribution network and step up marketing to new medical professionals.


Headquartered in Parsippany, New Jersey, Precision Spine is a medical device company specializing in spinal care. It handles a range of spinal implants and related medical devices and has more than 150 partners in the United States, Europe, the Middle East and other regions, including its subsidiaries Spinal USA and Precision Medical.


The agreement follows a sales deal signed with Medtronic in October for lumbar expandable cages. By securing a global medical device company and a specialized local distributor as partners, L&K Biomed has broadened its routes into the U.S. market for both lumbar and cervical product lines.


The company also sees policies to improve access to healthcare in the United States as a factor in market growth. It said demand for spinal surgery is increasing as more people become eligible for public health insurance programs such as Medicare and Medicaid, while interest is also growing in minimally invasive expandable cages that can reduce recovery time and hospital care costs. The U.S. spinal implant market is estimated to be worth about $10 billion (approximately 13 trillion won).


The company is also developing next-generation cervical products. In September, it began a technical collaboration with Dr. K. Daniel Riew, a cervical surgery specialist. The goal is to combine his clinical experience with the company's spinal implant design and manufacturing capabilities to develop products that address the needs of surgical teams. The company is also pursuing the New Cervical Project to expand its portfolio beyond expandable cages to include products such as corpectomy devices.


L&K Biomed is also collecting data related to BluEX-C. The company plans to use the data in developing smart systems integrated with artificial intelligence (AI), and to enhance the product's competitiveness and market recognition.



A representative of L&K Biomed said, "We expect the combination of our in-house sales infrastructure and Precision Spine's local distribution network to accelerate sales growth and deliver tangible revenue results in the U.S. market." The representative added, "As healthcare policy changes broaden the base of demand for spinal surgery, we will quickly increase BluEX-C's market share and sales performance."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing